Sonoma Pharmaceuticals Q1 revenue rises on US growth

Sonoma Pharmaceuticals

06/08/2026 14:07

Overview
US wound care products maker's fiscal Q1 revenue rose 60% yr/yr
Net loss per share fell 88% from prior-year quarter
Gross margin expanded to 40% as operating expenses stayed flat

Outlook
Company says new FDA clearances and global distributors support continued commercial growth
Sonoma believes expanding partnerships and product pipeline position it for profitable growth

Result Drivers
US SALES GROWTH - Co attributed 141% increase in US revenue to higher sales of over-the-counter products and expanded distributor activity
GLOBAL DISTRIBUTION EXPANSION - Co added new distributors in Taiwan, Vietnam and US, supporting commercial growth
EUROPEAN DEMAND AND FX - Co said European revenue rose 34% due to increased demand and favorable exchange rates

Company press release: ID:nACSmqRk1a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
$6.4 mln
 
Q1 Gross Profit
 
$2.6 mln
 
Q1 Operating Expenses
 
$2.6 mln
 

Reuters Recommended Reads
Aug 6 - Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Aug 6 - Becton Dickinson raises lower end of annual profit forecast on drug delivery devices strength
Aug 6 - Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)